The European Medicines Agency (EMA) Network Data Steering Group (NDSG) will hold its annual meeting with industry stakeholders on 14 July 2026, focusing on progress in data methodology and guidance, as well as the impact of new EU legislation on data opportunities. The meeting, scheduled from 09:00 to 12:00 CET via Teams, is co-chaired by Karl Broich of the German Federal Institute for Drugs and Medical Devices (BfArM) and Peter Arlett of EMA.
The agenda includes a session on key progress of the NDSG workplan, covering methodology and guidance, with presentations from NDSG representatives and industry participants. Industry perspectives will be provided by Roberta Bernadelli (Gilead, EUCOPE) and Remco Munnik (Arcana, Medicines for Europe), followed by a 40-minute group discussion. A second session will look ahead to new EU legislation, examining its impact and opportunities for data, with industry inputs from Rodrigo Palacios (F. Hoffmann-La Roche, EFPIA) and Angela Mueller (Schwab Group, AESGP), also followed by group discussion.
The meeting will conclude with wrap-up and closing remarks by the co-chairs. A list of 19 industry participants includes representatives from Sanofi, GSK, Novartis, BMS, Merck Group, and Oracle Life Sciences, among others, covering associations such as EFPIA, EUCOPE, AESGP, Vaccines Europe, EuropaBio, ACRO, and Medicines for Europe.
The NDSG is an EMA expert group that coordinates the development and use of real-world data and evidence for regulatory decision-making. The annual meeting provides a forum for dialogue between regulators and industry on data-related priorities and challenges. No prior coverage of this specific meeting exists in the available record.